Mini-Focus: Guideline-Directed Medical Therapy (GDMT)Clinical ResearchCardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF
Clinical Research
Under an Elsevier user license
open archive
Central Illustration
Key Words
clinical outcomes
heart failure with preserved ejection fraction
mineralocorticoid receptor antagonists
renal outcomes
sacubitril/valsartan
Abbreviations and Acronyms
CI
confidence interval
CV
cardiovascular
eGFR
estimated glomerular filtration rate
ESRD
end-stage renal disease
HFpEF
heart failure with preserved ejection fraction
HFrEF
heart failure with reduced ejection fraction
HHF
hospitalization for heart failure
HR
hazard ratio
KCCQ-CSS
Kansas City Cardiomyopathy Questionnaire clinical summary score
LVEF
left ventricular ejection fraction
MRA
mineralocorticoid receptor antagonist
NT-proBNP
N-terminal pro–B-type natriuretic peptide
NYHA
New York Heart Association
OR
odds ratio
Cited by (0)
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center.
© 2021 by the American College of Cardiology Foundation. Published by Elsevier.